zuma-3: identifying the optimal dose of axi-cel in r/r all
Published 5 years ago • 72 plays • Length 2:19Download video MP4
Download video MP3
Similar videos
-
0:54
zuma-3 end of phase i results: axi-cel for r/r all
-
0:54
insights into the zuma-23 trial: axi-cel in frontline high-risk lbcl
-
2:52
zuma-24 preliminary analysis of axi-cel in the outpatient setting in patients with r/r lbcl
-
3:10
zuma-9: expanded access protocol and oos axicabtagene ciloleucel in r/r dlbcl
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
2:17
zuma-12: axicabtagene ciloleucel as a first-line therapy in patients with high-risk lbcl
-
3:56
the future of cancer treatment is here: introducing proton therapy
-
1:05:07
euretina case club with prof adnan tufail (nov 10th, 2021)
-
2:05
alnuctamab: improved route of administration and optimized dose level & dosing schedule
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
2:38
zuma-1 & scholar-1: comparison of outcomes in refractory dlbcl
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:45
ham-ven as salvage treatment for r/r aml: results from the sal-relax trial
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:53
the future of multiple myeloma treatment
-
1:33
all diagnostics: challenges and considerations
-
0:47
overview of the phase iii enhance trial schema
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:40
master class in transplantation and hematology: highlights
-
5:07
daratumumab in the management of al amyloidosis
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen